RNS Number : 7034M
ValiRx PLC
19 November 2024

19 November 2024

ValiRx PLC
("ValiRx" or the "Company")

Contract Award

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, provides the following contract award update from its wholly owned subsidiary Inaphaea BioLabs Limited ("Inaphaea").

Inaphaea is delighted to confirm the execution of a further contract for the provision of cell-based assays to UK biotech company, Amply Discovery Limited ("Amply"). The multiphase contract, potentially worth over £100,000 over a 8 month period, will evaluate various formulations of Amply's developmental siRNA targets in Inaphaea's Triple Negative Breast Cancer (TNBC) Patient Derived Cells (PDCs) as stand-alone agents and in combination with standard of care drugs. The deal includes an upfront payment to Inaphaea of approximately £31,000 with an additional approximately £21,000 payment on completion of the first phase after 4 months and £10,500 on completion of the remaining *in-vitro phase after a further 6 weeks*. Successful candidates have the option to be evaluated *in-vivo* using selected PDCs through one of Inaphaea's partners.

Andrew Carnegie, Head of Strategic Commercial Development at Inaphaea, commented"*It is exciting to have secured this contract, which aligns our services with one of our strategic partners, and defines a good roadmap for future clients*."

Mark Eccleston, CEO of ValiRx commented*"This is an important contract for Inaphaea as it validates our partnered approach to offering full-service capabilities to our clients."*

Dermot Tierney, COO of Amply commented*"We are happy to be working with Inaphaea on this critical phase of Amply's development pathway. It was important for us to find a CRO partner who could manage the whole process with agreed milestones."*

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018 ("UK MAR"). The Directors of the Company take responsibility for this announcement.

*** ENDS ***

For more information, please contact:

ValiRx plc Dr Mark Eccleston, CEO	**Tel: +44 (0) 2476 796496** **www.valirx.com** Mark.Eccleston@valirx.com
V Formation (Public Relations) Lucy Wharton - Senior PR Executive Sue Carr - Director	**+44 (0) 115 787 0206** **www.vformation.biz** lucy@vformation.biz sue@vformation.biz
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray/ Ludovico Lazzaretti	**Tel: +44 (0) 20 7213 0880**

Shard Capital Partners LLP (Sole Broker) Damon Heath	**Tel: +44 (0) 20 7186 9000**

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

For further information, visit:www.valirx.com

Cautionary statement

Certain statements made in this announcement are forward-looking statements. Such statements are based on current expectations and assumptions and are subject to a number of risks and uncertainties that could cause actual events or results to differ materially from any expected future events or results expressed or implied in these forward-looking statements. Persons receiving this announcement should not place undue reliance on forward-looking statements. Unless otherwise required by applicable law, regulation or accounting standard, the Company does not undertake to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

CNTXVLLFZFLFFBV